Anika Therapeutics, Inc.
NASDAQ:ANIKMedical - Devices
-$0.06 today
- Market cap
- $182.44M
- Beta
- 0.23
- P/E (TTM)
- -17.3
- EPS (TTM)
- -$0.82
Volume 0.12M
Average 0.11M
ANIK Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Anika Therapeutics, Inc.NASDAQ: ANIK
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $10.35M (cash outflow) rose 90.3% year over year, ahead of the -2.7% change in trailing-twelve-month financing cash flow. Sequentially, it rose 96.0% from the prior quarter. Over 3 fiscal years it compounded at +29.6% a year.
Context
- Financing cash flow amounted to 9.4% of revenue in FY2025, down 1.3 pp from a year earlier.
- Financing cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +90.3% holds above the trailing-twelve-month pace of -2.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (10.55M) USD
- Year-over-year change
- +17.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.55M) | +17.1% |
| FY2024 | 2024-12-31 | (12.73M) | -101.3% |
| FY2023 | 2023-12-31 | (6.32M) | -30.3% |
| FY2022 | 2022-12-31 | (4.85M) | +28.4% |
| FY2021 | 2021-12-31 | (6.78M) | — |
Financing Cash Flow vs competitors
How ANIK compares with its peers on the latest reported figures
- ANIK's LTM Mar 2026 financing cash flow of $15.46M is the 5th largest of the 9 companies compared; the peer median is $14.2M.
- Its year-over-year change of -2.7% is the 7th highest of 9, against a peer median of +109.9%.
- Financing cash flow amounts to 13.3% of revenue for ANIK, versus a peer median of 33.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $321.16M | +191.5% | -4.1% | 17350.5% |
| LTM Mar 2026 | $49.08M | +8.7% | +182.8% | 955.9% | |
| LTM Mar 2026 | $35.6M | +177.6% | — | 33.3% | |
| LTM Mar 2026 | $18.76M | +4324.8% | +205.6% | 54.6% | |
| LTM Mar 2026 | $15.46M | -2.7% | +29.6% | 13.3% | |
| LTM Mar 2026 | $9.64M | +42.3% | +253.4% | 17.2% | |
| LTM Apr 2026 | $5.21M | +1936.3% | +71.5% | — | |
| LTM Mar 2026 | $358K | -96.4% | — | 0.6% | |
| LTM Mar 2026 | $278K | -84.0% | -39.0% | 0.9% | |
| Peer median (excluding ANIK) | $14.2M | +109.9% | +127.1% | 33.3% | |
Competitors are the stored peer set for ANIK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 4.13M | (14.86M) | (82.67M) | (56.39M) | (10.88M) |
| Depreciation & Amortization | 14.32M | 14.49M | 14.22M | 8.12M | 5.73M |
| Deferred Income Tax | (1.77M) | (5.27M) | (6.33M) | 260K | (7K) |
| Stock-Based Compensation | 11.09M | 14.32M | 15.24M | 13.13M | 10.08M |
| Change in Working Capital | (14.72M) | (11.82M) | (12.12M) | (13.09M) | (823K) |
| Accounts Receivables | (6.22M) | (5.63M) | (1.31M) | 3.37M | 408K |
| Inventory | (6.62M) | (6.87M) | (11.4M) | (9.42M) | 30K |
| Accounts Payables | (1.1M) | 1.97M | (11K) | (2.51M) | 42K |
| Other Working Capital | (783K) | (1.28M) | 589K | (4.53M) | (1.3M) |
| Other Non-Cash Items | (4.66M) | 7.56M | 69.87M | 53.37M | 7.09M |
| Operating Cash Flow | 8.4M | 4.41M | (1.79M) | 5.4M | 11.19M |
| Capital Expenditures | (5.14M) | (7.49M) | (5.43M) | (7.73M) | (6.83M) |
| Acquisitions (Net) | (476K) | 0 | 0 | 0 | 8.99M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 2.5M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (600K) | (2.57M) |
| Investing Cash Flow | (3.12M) | (7.49M) | (5.43M) | (8.33M) | (401K) |
| Debt Repayment | (201K) | (284K) | 0 | 0 | 0 |
| Common Stock Issued | 1.13M | 681K | 0 | 0 | 500K |
| Common Stock Repurchased | 0 | 0 | (5M) | (10.91M) | (9.49M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.71M) | (5.25M) | (1.32M) | (1.82M) | (1.57M) |
| Financing Cash Flow | (6.78M) | (4.85M) | (6.32M) | (12.73M) | (10.55M) |
| Effect of Forex Changes | 69K | (130K) | 79K | (48K) | 86K |
| Net Change in Cash | (1.43M) | (8.06M) | (13.46M) | (15.71M) | 322K |
| Free Cash Flow | 3.25M | (3.08M) | (7.22M) | (2.33M) | 4.36M |
Anika Therapeutics, Inc.
NASDAQ:ANIK
Intrinsic Alpha fair value
Locked
Current Price
$13.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.